scholarly journals Analysis of copy number variants and segmental duplications in the human genome: Evidence for a change in the process of formation in recent evolutionary history

2008 ◽  
Vol 18 (12) ◽  
pp. 1865-1874 ◽  
Author(s):  
P. M. Kim ◽  
H. Y.K. Lam ◽  
A. E. Urban ◽  
J. O. Korbel ◽  
J. Affourtit ◽  
...  
PLoS Biology ◽  
2020 ◽  
Vol 18 (11) ◽  
pp. e3000926 ◽  
Author(s):  
Young Mi Kwon ◽  
Kevin Gori ◽  
Naomi Park ◽  
Nicole Potts ◽  
Kate Swift ◽  
...  

Devil facial tumour 1 (DFT1) is a transmissible cancer clone endangering the Tasmanian devil. The expansion of DFT1 across Tasmania has been documented, but little is known of its evolutionary history. We analysed genomes of 648 DFT1 tumours collected throughout the disease range between 2003 and 2018. DFT1 diverged early into five clades, three spreading widely and two failing to persist. One clade has replaced others at several sites, and rates of DFT1 coinfection are high. DFT1 gradually accumulates copy number variants (CNVs), and its telomere lengths are short but constant. Recurrent CNVs reveal genes under positive selection, sites of genome instability, and repeated loss of a small derived chromosome. Cultured DFT1 cell lines have increased CNV frequency and undergo highly reproducible convergent evolution. Overall, DFT1 is a remarkably stable lineage whose genome illustrates how cancer cells adapt to diverse environments and persist in a parasitic niche.


2020 ◽  
Vol 103 (3) ◽  
pp. 1073-1088
Author(s):  
Gianluca Bretani ◽  
Laura Rossini ◽  
Chiara Ferrandi ◽  
Joanne Russell ◽  
Robbie Waugh ◽  
...  

2006 ◽  
Vol 38 (10) ◽  
pp. 1216-1220 ◽  
Author(s):  
Adnan Derti ◽  
Frederick P Roth ◽  
George M Church ◽  
C-ting Wu

2007 ◽  
Vol 104 (24) ◽  
pp. 10110-10115 ◽  
Author(s):  
J. O. Korbel ◽  
A. E. Urban ◽  
F. Grubert ◽  
J. Du ◽  
T. E. Royce ◽  
...  

2013 ◽  
Vol 202 (1) ◽  
pp. 5-6 ◽  
Author(s):  
David St Clair

SummaryCopy number variants are small chromosomal deletions and duplications. When they alter the dose of genes critical for normal brain development and adult brain functioning they may cause severe disorders such as autism and schizophrenia. Numerous such loci have recently been identified. They are offering amazing leads for neuropsychiatric research.


2007 ◽  
Vol 39 (S7) ◽  
pp. S22-S29 ◽  
Author(s):  
Gregory M Cooper ◽  
Deborah A Nickerson ◽  
Evan E Eichler

2007 ◽  
Vol 9 (9) ◽  
pp. 600-606 ◽  
Author(s):  
Laia Rodriguez-Revenga ◽  
Montserrat Mila ◽  
Carla Rosenberg ◽  
Allen Lamb ◽  
Charles Lee

2009 ◽  
Vol 4 (2) ◽  
pp. 71-72
Author(s):  
Thomas J. Nicholas ◽  
Ze Cheng ◽  
Katrina L. Mealey ◽  
Evan E. Eichler ◽  
Joshua M. Akey

2005 ◽  
Vol 77 (1) ◽  
pp. 78-88 ◽  
Author(s):  
Andrew J. Sharp ◽  
Devin P. Locke ◽  
Sean D. McGrath ◽  
Ze Cheng ◽  
Jeffrey A. Bailey ◽  
...  

Author(s):  
Justin Wagner ◽  
Nathan D Olson ◽  
Lindsay Harris ◽  
Ziad Khan ◽  
Jesse Farek ◽  
...  

AbstractGenome in a Bottle (GIAB) benchmarks have been widely used to help validate clinical sequencing pipelines and develop new variant calling and sequencing methods. Here we use accurate long and linked reads to expand the prior benchmark to include difficult-to-map regions and segmental duplications that are not readily accessible to short reads. Our new benchmark adds more than 300,000 SNVs, 50,000 indels, and 16 % new exonic variants, many in challenging, clinically relevant genes not previously covered (e.g., PMS2). We increase coverage of the autosomal GRCh38 assembly from 85 % to 92 %, while excluding problematic regions for benchmarking small variants (e.g., copy number variants and assembly errors) that should not have been in the previous version. Our new benchmark reliably identifies both false positives and false negatives across multiple short-, linked-, and long-read based variant calling methods. As an example of its utility, this benchmark identifies eight times more false negatives in a short read variant call set relative to our previous benchmark, mostly in difficult-to-map regions. To enable robust small variant benchmarking, we still exclude 3.6% of GRCh37 and 5.0% of GRCh38 in (1) highly repetitive regions such as large, highly similar segmental duplications and the centromere not accessible to our data and (2) regions where our sample is highly divergent from the reference due to large indels, structural variation, copy number variation, and/or errors in the reference (e.g., some KIR genes that have duplications in HG002). We have demonstrated the utility of this benchmark to assess performance in more challenging regions, which enables benchmarking in more difficult genes and continued technology and bioinformatics development. The v4.2.1 benchmarks are available under ftp://ftp-trace.ncbi.nlm.nih.gov/ReferenceSamples/giab/release/AshkenazimTrio/.


Sign in / Sign up

Export Citation Format

Share Document